- Home
- CADL vs SNN Comparison
CADL vs SNN Comparison
Compare CADL & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CADL
- SNN
- Stock Information
- Founded
- CADL 1999
- SNN 1856
- Country
- CADL United States
- SNN United Kingdom
- Employees
- CADL N/A
- SNN N/A
- Industry
- CADL Biotechnology: Pharmaceutical Preparations
- SNN Industrial Specialties
- Sector
- CADL Health Care
- SNN Health Care
- Exchange
- CADL Nasdaq
- SNN Nasdaq
- Market Cap
- CADL 339.8M
- SNN 13.2B
- IPO Year
- CADL 2021
- SNN 1999
- Fundamental
- Price
- CADL $5.60
- SNN $36.35
- Analyst Decision
- CADL Strong Buy
- SNN Hold
- Analyst Count
- CADL 6
- SNN 4
- Target Price
- CADL $20.33
- SNN $33.50
- AVG Volume (30 Days)
- CADL 911.4K
- SNN 682.0K
- Earning Date
- CADL 11-13-2025
- SNN 10-30-2025
- Dividend Yield
- CADL N/A
- SNN 2.01%
- EPS Growth
- CADL N/A
- SNN 59.91
- EPS
- CADL N/A
- SNN 0.56
- Revenue
- CADL N/A
- SNN $5,944,000,000.00
- Revenue This Year
- CADL N/A
- SNN $7.75
- Revenue Next Year
- CADL N/A
- SNN $5.40
- P/E Ratio
- CADL N/A
- SNN $31.14
- Revenue Growth
- CADL N/A
- SNN 5.35
- 52 Week Low
- CADL $3.79
- SNN $23.69
- 52 Week High
- CADL $14.60
- SNN $38.79
- Technical
- Relative Strength Index (RSI)
- CADL 48.96
- SNN 53.93
- Support Level
- CADL $5.26
- SNN $34.69
- Resistance Level
- CADL $6.27
- SNN $36.06
- Average True Range (ATR)
- CADL 0.47
- SNN 0.44
- MACD
- CADL -0.04
- SNN 0.05
- Stochastic Oscillator
- CADL 32.61
- SNN 77.57
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.